Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Net Margin (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Net Margin for 11 consecutive years, with 178.39% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 36893.0% to 178.39% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 296.25% through Dec 2025, down 21502.0% year-over-year, with the annual reading at 296.53% for FY2025, 21528.0% down from the prior year.
  • Net Margin hit 178.39% in Q4 2025 for Voyager Therapeutics, up from 208.69% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1524.26% in Q4 2022 to a low of 3239.97% in Q1 2022.
  • Historically, Net Margin has averaged 579.3% across 5 years, with a median of 301.01% in 2021.
  • Biggest five-year swings in Net Margin: tumbled -284665bps in 2022 and later soared 332240bps in 2023.
  • Year by year, Net Margin stood at 20.34% in 2021, then skyrocketed by 7395bps to 1524.26% in 2022, then tumbled by -96bps to 62.59% in 2023, then tumbled by -975bps to 547.33% in 2024, then skyrocketed by 67bps to 178.39% in 2025.
  • Business Quant data shows Net Margin for VYGR at 178.39% in Q4 2025, 208.69% in Q3 2025, and 641.96% in Q2 2025.